News from viacyte, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 18, 2014, 09:00 ET
ViaCyte logo.

Study Further Validates Cell Therapy Approach to Reverse Type 1 Diabetes

ViaCyte, Inc. announced today a preclinical study published online in Cell Stem Cell that describes a novel approach to replace the...

Nov 20, 2014, 09:00 ET
ViaCyte logo.

ViaCyte to Present at 26th Annual Piper Jaffray Healthcare Conference

ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Nov 06, 2014, 09:00 ET
After implant into animals in pre-clinical studies of VC-01, the PEC-01 cells mature into the various human cell types of the endocrine pancreas, including those expressing insulin (INS, blue), glucagon (GCG, red), and somatostatin (SST, green).

ViaCyte Receives U.S. Patent Claiming Alternative Methods to Manufacture Pancreatic Progenitor Cells In Vitro

 ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Oct 29, 2014, 09:00 ET
ViaCyte logo.

ViaCyte's VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted into First Patient

ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the first patient in its Phase 1/2 study was successfully...

Oct 06, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. to Present at Upcoming Stem Cell Meeting on the Mesa Conference

ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Sep 10, 2014, 15:21 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of its VC-01™ Diabetes Therapy Candidate

 ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Aug 21, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.

ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research...

Aug 19, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01™ Candidate Cell Replacement Therapy for Type 1 Diabetes

ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the...

Aug 08, 2014, 10:09 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte, Inc. Raises $5.4 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product VC-01™ for Insulin-Dependent Diabetes

 ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of...

Jul 17, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes

ViaCyte, Inc., a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, today announced...

Jul 08, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Achieves Significant Milestone with ISO 13485:2003 Certification for its Encaptra Drug Delivery System

 ViaCyte, Inc. ("ViaCyte"), a privately held regenerative medicine company developing a cell therapy for treatment of type I diabetes, today...

May 29, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte and Asterias Biotherapeutics Settle Patent Dispute

 ViaCyte, Inc., a regenerative medicine company focused on developing a cell replacement therapy for the treatment of patients with...

Feb 06, 2014, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

JDRF to Provide Additional Support for Upcoming Clinical Trial of ViaCyte's Encapsulated Cell Therapy for Type 1 Diabetes

JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and ViaCyte, Inc., a leading regenerative medicine company,...

Dec 19, 2013, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors

 ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today...

Dec 02, 2013, 13:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte to Present at the 25th Piper Jaffray Healthcare Conference

 ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today...

Oct 29, 2013, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine

ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a...

Oct 16, 2013, 11:56 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte to Present at the JDRF 8th Annual T1D Global Path to a Cure Symposium

ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced...

Oct 10, 2013, 14:12 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte To Present Update On VC-01™ Combination Product Development At 2013 Stem Cell Meeting On The Mesa

ViaCyte, Inc. announced today that an update on the Company's progress toward a transformative stem cell-derived cell therapy for the treatment of...

Jul 10, 2013, 06:00 ET

ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes

 ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application...

Jan 31, 2013, 09:00 ET
ViaCyte logo.  (PRNewsFoto/ViaCyte, Inc.)

ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a...